United States Joins Suits Against Scios and Johnson & Johnson
Pharmaceutical Companies Allegedly Marketed the Drug Natrecor for a Use Not Approved By the Food and Drug Administration
WASHINGTON, Feb. 19 /PRNewswire-USNewswire/ -- The United States has intervened in two whistleblower suits filed in the Northern District of California against the d...
Jane Moffitt, J.D., LL.M. Named Vice President of Regulatory Affairs of Nile Therapeutics
...unction and was the
head of the regulatory affairs function. Ms. Moffitt also served as
President, Treasurer and a member of the Board of Directors of scios
Inc. and BRP, Inc.
Ms Moffitt holds a B.S. in Biology and Political Science from Dickinson
College, a J.D. from Dickinson School of Law and a L...
ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
...yed a pivotal role in the successful
launch and commercialization of Natrecor, a recombinant form of BNP for
acute heart failure. During his tenure at scios
he created and built a
sales organization from the bottom up.
"At this critical juncture, we welcome Randy as an important addition
to our team as w...
New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment
... to drive early detection and treatment of the
pervasive condition, and to advance disease prevention. Fight Against Heart
Failure(SM) is sponsored by scios
Inc., which has provided educational
grants to AAHFN, PCNA and SCPC to conduct this program.
According to the survey: -- Less than half of U.S...
Study Supports Controversial Heart Failure Drug
...e," Witteles said.
Critics quickly put the pressure on the drug's maker, scios
Inc., to initiate a large, prospective randomized controlled trial. Such a ...zers hope to gather 7,000 patients.
The Stanford study -- also funded by scios
-- was much smaller and was conceived before the controversy broke, Wittele...
Manufacturer to Pay $20 Million for Improperly Promoting a Sleep Disorder Drug
Although the FDA has approved Natrecor's sale to people with congestive heart failure who have trouble breathing while doing minimal activity, scios
has been accused of improperly promoting frequent injections of the drug in out-patient settings.
South San Francisco-based Genentech also has...
New FDA Approved Drug NATRECOR For Heart Failure Patients
Studies showed patients could breathe better as blood circulation and lung congestion improved with Natrecor treatment. California-based scios
Pharmaceuticals said it will start shipping Natrecor to hospitals this week and each vial, a day's treatment, will cost $380. ...
Jennerex Appoints Samantha Miller as Vice President of Corporate Development
.... Miller has held senior positions in business development, including
the title of Vice President, in various companies including Anesiva,
Pharmaceuticals, Onyx Pharmaceuticals and Procter & Gamble
"Samantha is an outstanding addition to our executive managemen...
Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
...ed Leadership Capable of Driving Value
-- Chief Executive Officer: Richard B. Brewer, current president and
CEO of ARCA, former president and CEO of scios
and senior vice president of
sales and marketing of Genentech;
-- Chief Science and Medical Officer: Michael R. Bristow, MD, PhD,
current chairman a...